Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pfizer Inc. (PFE) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, with AI‑powered tools to help interpret complex documents. As a large issuer in the pharmaceutical preparation manufacturing industry, Pfizer files a wide range of reports that are important for understanding its operations, capital structure and risk profile.
Investors can review Form 8‑K current reports that describe material events such as financial results, public offerings of notes, acquisitions and guidance updates. Recent 8‑K filings detail second‑ and third‑quarter 2025 financial results, full‑year 2025 and 2026 revenue and adjusted EPS guidance, a multi‑tranche public offering of senior notes with maturities extending to 2065, and the completed acquisition of Metsera, a company developing GLP‑1‑based obesity therapies.
Pfizer’s 8‑Ks also reference shelf registration statements and supplemental indentures governing its debt securities, as well as underwriting and pricing agreements with major investment banks. These filings help users track how Pfizer raises long‑term capital and manages its balance sheet. Other 8‑Ks furnish press releases under Regulation FD, including guidance updates that outline expected revenue contributions from COVID‑19 products and the impact of loss of exclusivity on certain medicines.
On Stock Titan, AI‑generated summaries highlight the key points of lengthy filings, explaining in plain language what new debt offerings, acquisitions, guidance changes or other events may mean for the company. Users can quickly identify which exhibits relate to indentures, legal opinions or merger agreements, and can follow how Pfizer’s financing activities and strategic transactions evolve over time.
In addition to 8‑Ks, this page links to Pfizer’s other core SEC reports, such as annual and quarterly filings, where available. Together, these documents provide a regulatory record of Pfizer’s financial performance, risk factors, capital markets activity and major corporate actions, with AI assistance to make the information more accessible.
Baum Andrew reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Andrew Baum reported an equity compensation grant in the form of 303,151 stock appreciation rights. These stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.
Pfizer Inc. Executive Vice President Lidia Fonseca reported receiving a grant of 82,284 stock appreciation rights on Pfizer common stock. These rights were acquired as a compensation award at a price of $0.0000 per right and are held as direct ownership.
According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, Fonseca held a total of 82,284 stock appreciation rights.
Pfizer Inc. Executive Vice President Michael McDermott received a grant of 151,576 Stock Appreciation Rights on March 3, 2026. These rights were acquired at a price of $0.00 per right as a form of equity-based compensation.
According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, McDermott directly holds 151,576 stock appreciation rights.
SAHNI PAYAL reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Payal Sahni received a grant of 108,268 stock appreciation rights. These derivative awards were granted at a price of $0.00 per right and are scheduled to be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, subject to vesting requirements.
de Germay Alexandre reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Alexandre de Germay received a grant of 194,883 stock appreciation rights on Pfizer common stock. These rights were awarded at no purchase price and are classified as a derivative security. According to the terms, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported a tax-related share disposition. On February 27, 2026, 655 shares of Pfizer common stock at $27.65 per share were withheld to cover tax obligations upon the vesting of restricted stock units, leaving her with 12,041 directly owned shares.
Pfizer Executive Vice President Payal Sahni reported transactions tied to stock appreciation rights. She exercised stock appreciation rights for 56,888 shares of common stock on February 25, 2026, at a stated exercise price of $33.82 per share, increasing her direct holdings.
To cover related tax obligations and exercise costs, 1,083 shares at $27.09 per share and 54,066 shares at $26.92 per share were withheld, classified as tax-withholding dispositions rather than open-market sales. After these transactions, she directly owned 27,667 Pfizer common shares and indirectly held 14,630 shares through a Rule 16b-3 plan.
Pfizer Inc. Executive Vice President Douglas M. Lankler settled stock-based compensation tied to stock appreciation rights on February 25, 2026. He exercised 122,907 stock appreciation rights, receiving the same number of Pfizer common shares at a reference price of $33.82 per share.
To cover related tax obligations and exercise price, 2,198 shares were withheld at $27.09 per share and 116,811 shares were withheld at $26.92 per share. Following these transactions, he held 163,177 shares of Pfizer common stock directly and 2,083 shares indirectly through a Rule 16b-3 plan.
Pfizer Inc. senior vice president and controller Jennifer B. D'Amico reported transactions tied to stock appreciation rights (SARs). On earn-out of these SARs, she acquired 17,558 shares of Pfizer common stock through an exercise or conversion at a reference price of $33.82 per share. In connection with the earn-out, 361 shares at $27.09 per share and 16,687 shares at $26.92 per share were withheld to cover tax obligations and the exercise price. After these tax-withholding dispositions, she directly owned 12,696 shares of Pfizer common stock. These moves reflect equity compensation settlement rather than open-market buying or selling.
Pfizer Inc. Chairman & CEO Albert Bourla reported multiple equity transactions involving stock appreciation rights and common shares. On February 25, 2026, he exercised 491,626 stock appreciation rights, which were settled in an equal number of Pfizer common shares at $33.82 per share.
According to the footnotes, this earn-out included dividend equivalents and used a 20-day average of Pfizer’s closing prices to determine settlement. To cover the exercise price and related tax obligations, 467,241 and 8,303 common shares were withheld at prices of $26.92 and $27.09 per share, categorized as tax-withholding dispositions rather than open-market sales.
After these transactions, Bourla directly owned 388,671 Pfizer common shares and indirectly held 6,003 additional shares through a Rule 16b-3 plan. The filing reflects an exercise and settlement of incentive awards with associated share withholding, rather than discretionary market trading.